UT MD Anderson CC
Welcome,         Profile    Billing    Logout  
 1 Trial 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ueno, Naoto
NCT02689427: Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Completed
2
24
US
Axillary Lymph Node Dissection, ALND, Axillary Dissection, Axillary Lymphadenectomy, Axillary Node Dissection, Excision Axillary Lymph Nodes, Enzalutamide, ASP9785, MDV3100, Xtandi, Laboratory Biomarker Analysis, Lymph Node Biopsy, Biopsy of Lymph Node, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
11/23
11/23
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting
1/2
1123
US, RoW
DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327
DualityBio Inc., BioNTech SE
Advanced Solid Tumor
06/25
06/25
NCT05198843: Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

Terminated
1/2
1
US
Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Icosapent Ethyl, (all-Z)-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester, AMR 101, AMR101, Cis-Eicosapentaenoic Acid Ethyl Ester, Ethyl Icosapentate, Vascepa
National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Inflammatory Carcinoma
12/23
12/23
DROPLET-BC, NCT04671498: Droplet-BC Screening Test for the Detection of Breast Cancer, the Study

Recruiting
N/A
1200
US
Biospecimen Collection, Droplet-BC Test, Electronic Health Record Review
Preferred Medicine, Inc, M.D. Anderson Cancer Center
Breast Carcinoma
12/22
12/22
NCI-2018-01784, NCT00477100: Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients with Inflammatory or Invasive Breast Cancer

Recruiting
N/A
1200
US
Biospecimen Collection, Interview, Medical Chart Review, Chart Review, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Texas Appropriation for Rare and Aggressive diseases
Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Second Primary Malignant Neoplasm
04/30
04/30
Kizzee, Olaia
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
Moabbi, Jason
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ueno, Naoto
NCT02689427: Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Completed
2
24
US
Axillary Lymph Node Dissection, ALND, Axillary Dissection, Axillary Lymphadenectomy, Axillary Node Dissection, Excision Axillary Lymph Nodes, Enzalutamide, ASP9785, MDV3100, Xtandi, Laboratory Biomarker Analysis, Lymph Node Biopsy, Biopsy of Lymph Node, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
11/23
11/23
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting
1/2
1123
US, RoW
DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327
DualityBio Inc., BioNTech SE
Advanced Solid Tumor
06/25
06/25
NCT05198843: Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

Terminated
1/2
1
US
Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Icosapent Ethyl, (all-Z)-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester, AMR 101, AMR101, Cis-Eicosapentaenoic Acid Ethyl Ester, Ethyl Icosapentate, Vascepa
National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Inflammatory Carcinoma
12/23
12/23
DROPLET-BC, NCT04671498: Droplet-BC Screening Test for the Detection of Breast Cancer, the Study

Recruiting
N/A
1200
US
Biospecimen Collection, Droplet-BC Test, Electronic Health Record Review
Preferred Medicine, Inc, M.D. Anderson Cancer Center
Breast Carcinoma
12/22
12/22
NCI-2018-01784, NCT00477100: Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients with Inflammatory or Invasive Breast Cancer

Recruiting
N/A
1200
US
Biospecimen Collection, Interview, Medical Chart Review, Chart Review, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Texas Appropriation for Rare and Aggressive diseases
Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Second Primary Malignant Neoplasm
04/30
04/30
Kizzee, Olaia
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
Moabbi, Jason
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24

Download Options